VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AHS 2022 | Eptinezumab: the first approved infusion medication for migraine prevention

Rami Apelian, MD, MPH, FAES, Huntington Headache and Neurology, Arcadia, CA, discusses the impact of eptinezumab in the treatment of migraine. Many medications have been developed over the past few years to treat migraines – especially targeting calcitonin gene-related peptide (CGRP). However, eptinezumab is the first and only FDA-approved infusion of a monoclonal antibody targeting CGRP, helping prevent pain transmission and inflammatory response. This provides a new mechanism of delivery of an already established class of drugs to help ease migraines. This interview took place during the 2022 American Headache Society (AHS) Meeting in Denver, CO.

Disclosures

Rami Apelian received compensation as a consultant/speaker for Lundbeck, Lilly, Teva, Abbvie, and Biohaven